First-in-Human Serum Stability Studies of [ 177 Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.269132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Veronika Felber und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, TUM School of Natural Sciences, Technical University of Munich, Garching, Germany. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Lutetium, Radioisotopes, Receptors, Bombesin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The use of PET/CT with gastrin-releasing peptide receptor (GRPR) ligand [68Ga]Ga-AMTG has recently been shown to diagnose metastatic disease not detected by 18F-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer. This study aimed to analyze the serum stability of [177Lu]Lu-AMTG in human subjects due to the compound's high stability observed preclinically and to elucidate its therapeutic potential.
Methods
Blood samples were collected at various time points after intravenous injection of 7.6 ± 0.1 GBq of [177Lu]Lu-AMTG and centrifuged. Serum samples were analyzed via reversed-phase high-performance liquid chromatography.
Results
At 1 h after injection, the mean ± SD in vivo serum stability of [177Lu]Lu-AMTG was distinctly higher (62% ± 6%) than that of [68Ga]Ga-RM2 (19% ± 2%).
Conclusion
Based on the high in vivo serum stability of [177Lu]Lu-AMTG in humans and favorable biodistribution, radiolabeled AMTG derivatives have the potential to improve radiopharmaceutical therapy for GRPR-expressing malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, TUM School of Natural Sciences, Technical University of Munich, Garching, Germany.
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany.
- Department of Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; and.
- Molecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, California tgunther@stanford.edu bernd.krause@med.uni-rostock.de.
- Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany; tgunther@stanford.edu bernd.krause@med.uni-rostock.de.
Zitieren
APA
Felber, V., Holzleitner, N., Joksch, M., Suhrbier, T., von Amsberg, G., Schwarzenböck, S., Kurth, J., Heuschkel, M., Günther, T., & Krause, B. J. (2025). First-in-Human Serum Stability Studies of [ 177 Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.269132
Vancouver
Felber V, Holzleitner N, Joksch M, Suhrbier T, von Amsberg G, Schwarzenböck S, et al. First-in-Human Serum Stability Studies of [ 177 Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.269132
BibTeX
@article{Felber2025,
author = {Felber, Veronika and Holzleitner, Nadine and Joksch, Markus and Suhrbier, Tim and von Amsberg, Gunhild and Schwarzenböck, Sarah and Kurth, Jens and Heuschkel, Martin and Günther, Thomas and Krause, Bernd J},
title = {First-in-Human Serum Stability Studies of [ 177 Lu]Lu-AMTG: A Step Toward Improved GRPR-Targeted Radiopharmaceutical Therapy},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.269132}
}
EUVIMED